Cagrilintide: Research & Studies

Research Overview#

Cagrilintide has a substantial and growing clinical evidence base, with published data from multiple randomized controlled trials. The clinical development program, led by Novo Nordisk, has evaluated cagrilintide both as a standalone agent and in combination with semaglutide (marketed under the development name CagriSema). The evidence includes a phase 2 dose-finding study for monotherapy, a phase 2 study of the combination in type 2 diabetes, and multiple phase 3 trials (the REDEFINE program) that are either completed or ongoing.

The clinical evidence for cagrilintide is significantly more robust than for most investigational peptides, as it has been evaluated in properly designed, randomized, double-blind, placebo-controlled trials with clinically relevant endpoints. The evidence quality is classified as moderate overall, reflecting the availability of phase 2 and emerging phase 3 data, with the primary limitation being the absence of long-term safety and cardiovascular outcome data.

Phase 2 Dose-Finding Study (Lau et al., 2021)#

The pivotal phase 2 dose-finding study published in The Lancet (PMID: 34798060) was a multicentre, randomized, double-blind, placebo-controlled and active-controlled trial that evaluated five dose levels of cagrilintide monotherapy in adults with overweight or obesity. The study was conducted at 57 sites in ten countries.

Participants were randomized to receive once-weekly subcutaneous cagrilintide at doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, once-daily liraglutide 3.0 mg (active comparator), or placebo. The primary endpoint was percentage change in body weight from baseline at 26 weeks.

The results demonstrated clear dose-dependent weight loss. At 26 weeks, participants receiving cagrilintide 4.5 mg achieved mean body weight reduction of 10.8%, compared to 9.0% with 2.4 mg and 3.0% with placebo. The highest cagrilintide dose exceeded liraglutide 3.0 mg (9.0% weight loss). These results established cagrilintide as a potent standalone anti-obesity agent and confirmed the clinical relevance of amylin receptor agonism for weight management.

The adverse event profile was consistent with the known class effects of amylin analogs, with nausea being the most frequently reported side effect (20 to 47% across cagrilintide dose groups versus 18% with placebo).

Phase 1b Combination Study (Enebo et al., 2021)#

A separate phase 1b trial (PMID: 33894838) evaluated the safety, pharmacokinetics, and pharmacodynamics of cagrilintide co-administered with semaglutide 2.4 mg weekly. Six sequential cohorts tested cagrilintide at 0.16 to 4.5 mg in combination with semaglutide.

The combination produced striking weight loss results. At 20 weeks, cagrilintide 2.4 mg plus semaglutide 2.4 mg produced approximately 15.7% weight loss, substantially exceeding the weight loss achieved by semaglutide alone during the same period. This result provided the first clinical evidence that the combination of amylin and GLP-1 receptor agonism produces additive or synergistic weight loss, supporting the CagriSema development program.

The combination was well tolerated with an acceptable safety profile. Most adverse events were mild to moderate gastrointestinal effects, primarily nausea, occurring during the dose-titration phase.

CagriSema in Type 2 Diabetes (Frias et al., 2023)#

The phase 2 study published in The Lancet (PMID: 37364590) evaluated CagriSema specifically in patients with type 2 diabetes, a population where both the glycaemic and weight loss effects of the combination are clinically relevant.

This multicentre, randomized, double-blind trial compared CagriSema with the individual components (cagrilintide alone and semaglutide alone) and placebo. The study enrolled patients with type 2 diabetes who were inadequately controlled on metformin or diet alone.

CagriSema demonstrated superior HbA1c reduction compared to semaglutide alone, which was notable given that semaglutide is already one of the most potent GLP-1 receptor agonists for glycaemic control. The weight loss with CagriSema also exceeded that of either individual component. These results provided evidence that the benefits of the combination extend to the diabetic population and are not limited to weight loss alone.

The safety and tolerability profile in the diabetic population was generally consistent with the phase 2 obesity study, with gastrointestinal events being the most common adverse effects. The risk of hypoglycemia was low, consistent with the mechanisms of action of both components (neither directly stimulates insulin secretion in a glucose-independent manner).

Amylin Biology and Therapeutic Rationale#

The review by D'Ascanio and Akolkar (PMID: 36883831) published in Cardiology in Review provides comprehensive context for understanding the scientific rationale behind cagrilintide development. The review covers the physiology of amylin secretion and signaling, the receptor pharmacology of the amylin receptor system, the clinical experience with pramlintide (the first-generation amylin analog), and the development of long-acting amylin analogs including cagrilintide.

A key insight from this review is the complementarity between amylin and GLP-1 signaling pathways. While both hormones reduce appetite and food intake, they do so through partially distinct neuronal circuits. GLP-1 receptors are highly expressed in the hypothalamic arcuate nucleus and paraventricular nucleus, while amylin receptors are concentrated in the area postrema and nucleus of the solitary tract. The convergence of these signals on downstream circuits controlling energy balance provides the mechanistic basis for the synergistic weight loss observed with CagriSema.

REDEFINE Clinical Program (Phase 3)#

The REDEFINE program encompasses multiple phase 3 clinical trials evaluating CagriSema across different patient populations and clinical endpoints. These include REDEFINE 1 (obesity without diabetes), REDEFINE 2 (type 2 diabetes), REDEFINE 3 (obesity with knee osteoarthritis), and REDEFINE CVOT (cardiovascular outcomes trial).

Interim and top-line results from the REDEFINE program have demonstrated weight loss with CagriSema in the range of 20 to 25% of body weight, which represents a substantial advance over semaglutide alone (which typically produces 15 to 17% weight loss in the STEP program). These results position CagriSema as one of the most effective pharmacological approaches to obesity treatment currently in development.

The REDEFINE CVOT trial is particularly important for the long-term clinical positioning of CagriSema, as cardiovascular outcome data will be essential for regulatory approval and clinical adoption in patients with established cardiovascular disease or high cardiovascular risk.

Evidence Quality Assessment#

The evidence for cagrilintide is classified as moderate quality. This classification reflects the availability of well-designed randomized controlled trials published in high-impact peer-reviewed journals, replication of findings across multiple studies and populations, clinically meaningful endpoints with robust statistical analysis, and a coherent mechanistic rationale supported by preclinical data.

The primary limitations include the relatively short duration of published studies (maximum 26 weeks for the phase 2 monotherapy data), limited long-term safety data, absence of completed cardiovascular outcome trial data, and the fact that phase 3 results are primarily available as conference presentations rather than full publications.

Future Research Needs#

The most important unmet research needs for cagrilintide include the completion and publication of phase 3 REDEFINE trial results, long-term safety surveillance data (particularly for thyroid safety signals), cardiovascular outcome trial results, head-to-head comparisons with tirzepatide and other emerging obesity therapies, assessment of weight loss durability after treatment discontinuation, evaluation in special populations including adolescents and individuals with severe obesity, and characterization of effects on obesity-related comorbidities including non-alcoholic steatohepatitis and obstructive sleep apnea.

Related Reading#

• Cagrilintide overview and research guide
• Cagrilintide dosing protocols
• Cagrilintide molecular structure